{"organizations": [], "uuid": "2db3613265cacd80a431286f6057c12e1403280f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/15/globe-newswire-la-jolla-pharmaceutical-company-announces-pricing-of-public-offering-of-common-stock.html", "country": "US", "domain_rank": 767, "title": "La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-03-15T15:00:00.000+02:00", "replies_count": 0, "uuid": "2db3613265cacd80a431286f6057c12e1403280f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/15/globe-newswire-la-jolla-pharmaceutical-company-announces-pricing-of-public-offering-of-common-stock.html", "ord_in_thread": 0, "title": "La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock", "locations": [], "entities": {"persons": [{"name": "la joll", "sentiment": "negative"}, {"name": "la jolla", "sentiment": "none"}], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "la jolla pharmaceutical company announces pricing of public offering of common stock", "sentiment": "negative"}, {"name": "la jolla pharmaceutical company", "sentiment": "negative"}, {"name": "cowen", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of its underwritten public offering of 3,400,000 shares of its common stock at a price to the public of $29.50 per share, resulting in gross proceeds of approximately $100.3 million before underwriting discounts. In addition, La Jolla has granted the underwriter of the offering an option for a period of 30 days to purchase up to an additional 510,000 shares of the company's common stock at the public offering price, less the underwriting discount.\nCowen is acting as the sole book-running manager for the offering.\nLa Jolla intends to use the proceeds from the proposed sale of its shares of common stock for general corporate purposes, which include, but are not limited to, the continued commercialization of GIAPREZAâ„¢ (angiotensin II), funding its ongoing and future clinical trials of LJPC-401, preclinical development work and other administrative expenses.\nThe offering is expected to close on or about March 19, 2018, subject to satisfaction of customary closing conditions.\nThe offering is being made pursuant to a registration statement that was filed with the Securities and Exchange Commission and became effective on November 21, 2017. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Copies of the final prospectus supplement (when available) and accompanying prospectus relating to these securities may also be obtained by sending a request to: Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806.\nCompany Contacts\nSandra Vedrick\nDirector, Investor Relations & Human Resources\nLa Jolla Pharmaceutical Company\nPhone: (858) 207-4264 Ext: 1135\nEmail: svedrick@ljpc.com\nand\nDennis M. Mulroy\nChief Financial Officer\nLa Jolla Pharmaceutical Company\nPhone: (858) 207-4264 Ext: 1040\nEmail: dmulroy@ljpc.com\nSource:La Jolla Pharmaceutical Company", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/9b144999-cc1c-484a-a3cd-31dce41ddfaa", "https://www.globenewswire.com/Tracker?data=KV_I3G--kIBLAOaorBIXcNSpmNFcjwHMcd0HMZAyZ7riY4oUpuwfvV7dOY7V-frO3G7G4Ub9ZrqN6PCmYuXyRQ==", "https://www.globenewswire.com/Tracker?data=C6Es9SK0l4w29YDSAyk7TRyQ9PsJNdu2L1cOyRaVxC_ITvgHjINjRSJX4Qrb4v7Sl8GGrSD6fRdJMOnwuUAphQ=="], "published": "2018-03-15T15:00:00.000+02:00", "crawled": "2018-03-15T18:02:26.000+02:00", "highlightTitle": ""}